We conducted a case–control study to identify risk factors for hospitalization from pandemic (H1N1) 2009 virus infection among persons >16 years of age in Sydney, Australia. The study comprised 302 case-patients and 603 controls. In a logistic regression model, after adjusting for age and sex, risk factors for hospitalization were pregnancy (odds ratio [OR] 22.4, 95% confidence interval [CI] 9.2–54.5), immune suppression (OR 5.5, 95% CI 2.8–10.9), pre-existing lung disease (OR 6.6, 95% CI 3.8–11.6), asthma requiring regular preventive medication (OR 4.3, 95% CI 2.7–6.8), heart disease (OR 2.3, 95% CI 1.2–4.1), diabetes (OR 3.8, 95% CI 2.2–6.5), and current smoker (OR 2.0, 95% CI 1.3–3.2) or previously smoked (OR 2.0, 95% CI 1.3–3.0). Although obesity was not independently associated with hospitalization, it was associated with an increased risk of requiring mechanical ventilation. Public health messages should give greater emphasis to the risk for severe disease among pregnant women and smokers.

The emergence of pandemic (H1N1) 2009 virus (1,2) was associated with a large increase in the number of persons requiring hospitalization for severe influenza disease in many parts of the world (3–5). In response, in an effort to reduce the impact of the pandemic on their communities and health services, public health agencies developed recommendations for persons at increased risk for disease to seek early treatment. However, these recommendations were based on studies of seasonal influenza (6–10) and descriptive case reports (11–20).

The first cases of pandemic (H1N1) 2009 infection from New South Wales (NSW) were reported in May 2009. In NSW, laboratories were required to notify all pandemic (H1N1) 2009 diagnoses to the NSW Department of Health under Public Health Act 1991 (21). Australian public health management protocols recommended laboratory testing for all persons with influenza-like illness (fever and cough or sore throat) admitted to a hospital (22). Public health follow-up was required to ascertain hospitalization status for all notified cases at the time of diagnosis; this information was collated on a statewide database. Within Sydney, the capital city of NSW (population 4.4 million), there are 4 Area Health Services (AHSs) responsible for the provision of local public health and clinical services.

By the end of June 2009 (before a vaccine was available), community transmission was widespread in Australia, and public health efforts were focused on protecting those at greatest risk for severe disease. The groups considered most vulnerable were pregnant women; indigenous people; very obese persons; persons with pre-existing chronic medical conditions, including lung, heart, and kidney disease; and persons with blood, metabolic or neurologic disorders, immunosuppressive conditions, or asthma (23). Persons in these risk groups and those with severe disease were urged to seek medical attention early if influenza-like symptoms appeared. Doctors were provided with free antiviral medication for patients who were seen within 48 hours of symptom onset. A vaccine became publicly available for distribution in September 2009. To help reach populations who would most benefit from prevention and early intervention, we sought to identify independent risk factors for moderate to severe disease from pandemic (H1N1) 2009 infection among adults and to describe the characteristics of those who sought early medical treatment to determine the effectiveness of public health messages.
Methods
The study population was defined as persons >16 years of age residing in metropolitan Sydney during July 1–August 31, 2009. All interviews were conducted during September and October 2009.

Cases
We defined a case as a person with influenza-like illness admitted (for a minimum of an overnight stay) to a Sydney metropolitan hospital from July 1 through August 31, 2009, who had laboratory confirmation of pandemic (H1N1) 2009 by PCR that was notified to the Department of Health. Patients <16 years of age or residing outside metropolitan Sydney were excluded from the study because we assumed the threshold for hospital admission may have been different for this age group and for patients in regional and rural areas. To ensure complete case ascertainment, all cases notified in the study period were cross-matched with the Department of Health database containing all hospital admissions in NSW for the study period; additional identified cases were included in the study. If case-patients were not able to complete a telephone interview because of ill health or disability, another household member completed the interview on their behalf. Up to 30 attempts were made to contact case-patients by telephone.

Case–Control Study
In a case–control study, we compared demographic and health information reported by case-patients with those of controls. We defined a control as a person >16 years of age residing in metropolitan Sydney who had not been hospitalized for influenza in 2009. Telephone numbers (stratified by AHS) were used to randomly select potential control households. Within each AHS in Sydney, we selected 2 households per case. A single control was randomly selected from within each selected household for interview. Up to 12 attempts were made to contact selected households. Fewer attempts were made to contact controls than case-patients as a result of random-digit generation methods described in detail elsewhere (24). The age and sex distribution of participating controls was compared with that of the metropolitan Sydney population.

Study Questionnaire
We used a standard questionnaire to ask case-patients and controls about influenza symptoms, pregnancy or delivery within the previous 28 days, weight and height, smoking history, current and previous medications, and past hospitalizations. In addition, information was collected regarding diagnosis of general health conditions, including asthma, lung disease (defined as emphysema, chronic lung problems and/or chronic bronchitis), heart disease (defined as heart problems from birth, rheumatic heart disease, angina, heart attack, and/or heart failure excluding hypertension), diabetes (type I or II), other metabolic disorders, kidney disease (defined as kidney transplant, renal failure, and/or dialysis), liver disease, blood disorders (defined as sickle cell disease, thalassemia, or hemoglobin problems), mental health diagnoses, neurologic conditions (defined as conditions that involve muscles, nerves, or the brain), immune suppression (defined as cancer, HIV infection, or immunosuppressive medication), and obstructive sleep apnea. Ethics approval was not required because information was collected under NSW Public Health Act 1991 (21).

Statistical Analyses
In univariate analysis, the proportions of characteristics among case-patients and controls were compared by using χ2 tests. In multivariate analysis, independent risk factors for hospitalization were assessed through logistic regression by using backward elimination. All variables with a univariate level of significance p<0.25 were selected for inclusion in the base model, and variables were excluded if the p value was >0.05 and did not meaningfully alter the point estimates of the remaining variables. Because a similar proportion of case-patients and controls reported a diagnosis of asthma not requiring regular medication, only a history of asthma requiring regular medication was included in the final logistic regression model.

Additional logistic regression models were constructed to compare case-patients with controls for women of child-bearing age (16–45 years), case-patients who received mechanical ventilation compared with all controls, case-patients who sought medical attention within 48 hours of onset of symptoms compared with case-patients who sought medical attention after 48 hours, and controls who reported symptoms of influenza-like illness during the study period (defined as self-reported fever and either cough or sore throat) with controls who reported no illness during the study period. Mechanical ventilation (rather than intensive care unit admission) was used as a measure of severity of illness because cases were reported from several hospital facilities with varying criteria for patient admission to intensive care. The model fit the data well by the Hosmer-Lemeshow goodness-of-fit test (χ2 = 15.85, 9 df, p = 0.07). Seventy-nine percent of pairs were concordant, and c = 0.804.

Results
In total, 402 hospitalized patients were identified as eligible for inclusion in the study. Of these, 302 (75%) participated in the study, 27 (7%) refused interview, 66 (16%) were unable to be contacted, and 7 (2%) were excluded because of language difficulties. In univariate analysis, there was no significant difference between participating patients and nonparticipating patients with
respect to sex (p = 0.226), geographic location of residence (p = 0.341), indigenous status (p = 0.123), length of stay in hospital (p = 0.477), or ventilation status (p = 0.890). However, interviewed patients were significantly younger (median 45 years, range 16–88 years) than patients who were not interviewed (median 51 years, range 17–88 years) (p = 0.007).

Of 1,252 potential controls, 603 (48%) participated in the study. Of those remaining, 357 (28%) refused to participate, 153 (12%) were excluded because of language difficulties, and 139 (11%) were unavailable for interview. Of the controls, 25% were ages 16–35 years, 36% were 36–55 years, and 37% were >55 years. This compares with the adult metropolitan Sydney population of 38% ages 16–35 years, 36% 36–55 years, and 28% >55 years (Australian Bureau of Statistics, unpub. data).

**Descriptive Epidemiology**

The median age of case-patients was 45 years (range 16–88 years). Of the 302 case-patients, 125 (41%) were male, 68 (23%) were admitted to a high dependency or intensive care unit, and 37 (12%) required mechanical ventilation. The median length of hospital stay was 4 nights (range 1–91 nights). Reported risk factors among case-patients included a history of asthma (38%, including 29% who required regular medication), lung disease (19%), diabetes (19%), mental health diagnosis (18%), heart disease (14%), pregnancy (13%), obstructive sleep apnea (12%), immune suppression (10%), neurologic condition (8%), liver disease (8%), kidney disease (3%), blood disorders (5%), and metabolic conditions (1%) (online Appendix Table, www.cdc.gov/EID/content/17/8/100842-appT.htm).

None of the case-patients reported giving birth in 28 days before symptom onset. Of the 40 patients who were pregnant at the time of symptom onset, 28 (70%) were in their third trimester. Sixty-six (22%) case-patients were current smokers, and 91 (30%) were ex-smokers. Among the 91 ex-smokers, the median time smoked was 20 years (range 1–60 years, median 15 cigarettes/day); 39 reported cessation >5 years prior to illness, 15 patients between 12 months and 5 years, and 37 patients within the past 12 months. Among the 66 current smokers, the median time smoked was 20 years (range 1–60 years; median 10 cigarettes/day) (online Appendix Table).

**Case–Control Study**

There were no significant differences in characteristics of case-patients and controls by place of residence, receipt of 2009 seasonal influenza vaccination, or history of neurologic disorders (online Appendix Table). In univariate analysis, compared with controls, case-patients were more likely to be male, aged 16–35 years and 46–55 years, have higher body mass index (BMI), and report a history of asthma, heart disease, mental health diagnosis, immune suppression, obstructive sleep apnea, lung disease, diabetes, liver disease, blood disorder, and pregnancy, and smoking (online Appendix Table).

In the logistic regression model, age, sex, asthma (requiring regular medication), smoking (current or ex-smoker), heart disease, immune suppression, lung disease, diabetes, and pregnancy were independently associated with hospitalization for pandemic (H1N1) 2009 (Table 1). Similar results were found when analysis was restricted to men only or women only. The factor most strongly associated with hospitalization was pregnancy, followed by lung disease, immune suppression, and ages 16–25 and 46–55 years (Table 1). Overall, 262 (86%) case-patients reported ≥1 independent risk factor (asthma, heart disease, immune suppression, lung disease, diabetes, pregnancy, or smoking) compared with 315 (52%) of controls (p<0.0001). The risk for hospitalization increased with increasing number of reported significant risk factors.

In the logistic regression model for women of childbearing age, asthma (requiring regular medication), lung disease, diabetes, and pregnancy were independently associated with hospitalization for pandemic (H1N1) 2009 (Table 2). In total, 88% of women of childbearing age

**Table 1. Independent risk factors for hospitalization from pandemic (H1N1) 2009 influenza, all case-patients and controls, Sydney, Australia, 2009**

| Patient characteristic | Adjusted OR (95% CI) | p value |
|------------------------|----------------------|---------|
| **Sex**                |                      |         |
| M                      | 1.8 (1.2–2.5)        | 0.0017  |
| **Age, y**             |                      |         |
| 16–25                  | 5.4 (2.5–11.4)       |         |
| 26–35                  | 4.1 (2.0–8.3)        |         |
| 36–45                  | 3.9 (2.0–7.6)        | <0.0001 |
| 46–55                  | 5.1 (2.7–9.6)        |         |
| 56–65                  | 1.9 (1.0–2.5)        |         |
| >65                    | Referent             |         |
| **Underlying condition** |                     |         |
| Asthma, regular medication | 4.3 (2.7–6.8) | <0.0001 |
| Heart disease          | 2.3 (1.2–4.1)        | 0.0083  |
| Immunosuppression      | 5.5 (2.8–10.9)       | <0.0001 |
| Lung disease           | 6.6 (3.8–11.6)       | <0.0001 |
| Diabetes               | 3.8 (2.2–6.5)        | <0.0001 |
| Pregnancy              | 22.4 (9.2–54.5)      | <0.0001 |
| **Smoking status**     |                      |         |
| Nonsmoker              | Referent             |         |
| Current smoker         | 2.0 (1.3–3.2)        | 0.002   |
| Former smoker          | 2.0 (1.3–3.0)        |         |
| **No. significant risk factors** |               |         |
| 0                      | Referent             |         |
| 1                      | 3.9 (2.6–5.8)        |         |
| 2                      | 9.3 (5.9–14.6)       | <0.0001 |
| 3                      | 20.4 (10.4–40.2)     |         |
| >4                     | 80.3 (10.1–638.7)    |         |

*OR, odds ratio; CI, confidence interval.
hospitized for pandemic (H1N1) 2009 reported 1 of the risk factors compared with 39% of controls (p<0.0001). Pregnancy was the only risk factor reported for 25% of hospitalized women of childbearing age.

In univariate analysis, compared with controls, case-patients who required mechanical ventilation were more likely to report a history of lung disease, asthma (requiring regular medication), have a higher BMI, be pregnant, have an influenza vaccination in the previous 12 months, and be 26–45 years of age (Table 3). In the logistic regression model for ventilated case-patients, a history of lung disease, diabetes, pregnancy, high BMI, or status as a current or ex-smoker were independently associated with mechanical ventilation (Table 3).

Of the 603 controls, 113 (19%) reported an influenza-like-illness during the study period. There was no significant difference in underlying risk factors between controls who reported influenza-like-illness and controls who did not report any respiratory symptoms. However, influenza-like-illness was significantly more common among controls aged 16–25 (odds ratio [OR] 3.3, 95% confidence interval [CI] 1.4–7.5, p = 0.005) and 36–45 years (OR 3.0, CI 1.4–6.2, p = 0.004) compared with controls aged >65 years.

Information on the time from onset of illness to medical attention was available for 295 (98%) case-patients. Of these, 238 (81%) reported having ≥1 risk factor listed in the public message campaigns. Overall, the proportion of case-patients seeking medical attention was similar for

---

### Table 2. Risk factors for hospitalization caused by pandemic (H1N1) 2009 influenza for female case-patients and controls of childbearing age, Sydney, Australia, 2009*

| Patient characteristic | No. (%) case-patients, n = 99 | No. (%) controls, n = 181 | OR (95% CI) | p value | Adjusted OR (95% CI) | p value |
|------------------------|-------------------------------|---------------------------|-------------|---------|---------------------|---------|
| **Age, y**             |                               |                           |             |         |                     |         |
| 16–25                  | 28 (28)                       | 43 (24)                   | 1.4 (0.8–2.6) | 0.0003  |                     |         |
| 26–35                  | 37 (37)                       | 64 (35)                   | 1.3 (0.7–2.2) | 0.5233  |                     |         |
| 36–45                  | 34 (34)                       | 74 (41)                   | Referent    |         |                     |         |
| **Aboriginal status**  |                               |                           |             |         |                     |         |
| Nonindigenous          | 95 (98)                       | 177 (96)                  | Referent    | 0.3864  |                     |         |
| Indigenous             | 4 (4)                         | 4 (2)                     | 1.9 (0.5–7.6) | 0.0003  | 0.2457              | 0.0038  |
| **Body mass index†**   |                               |                           |             |         |                     |         |
| Underweight (<18.5)    | 8 (9)                         | 9 (5)                     | 2.8 (1.0–8.0) | 0.0003  | 1.3 (0.6–2.7)       | 0.0033  |
| Normal (18.5–24.9)     | 31 (33)                       | 99 (57)                   | Referent    | 0.0003  |                     |         |
| Overweight (25.0–29.9) | 15 (16)                       | 35 (20)                   | 1.4 (0.7–2.8) | 0.0003  |                     |         |
| Obese 1 (30.0–34.9)    | 17 (18)                       | 18 (10)                   | 3.0 (1.4–6.6) | 0.0003  |                     |         |
| Obese 2 (35.0–39.9)    | 10 (11)                       | 4 (2)                     | 8.0 (2.3–27.3) | 0.0003  |                     |         |
| Obese 3 (>40)          | 12 (13)                       | 8 (5)                     | 4.8 (1.8–12.8) | 0.0003  |                     |         |
| **Health condition‡**  |                               |                           |             |         |                     |         |
| Asthma                 | 46 (46)                       | 35 (19)                   | Referent    | 0.9871  |                     |         |
| No regular medication  | 7 (7)                         | 21 (12)                   | 0.9 (0.4–2.3) | <0.001  | 0.9871              | 0.9871  |
| Regular medication     | 39 (39)                       | 14 (8)                    | 7.7 (3.9–15.3) | 0.0003  |                     |         |
| Heart disease§         | 0                             | 1 (0.5)                   | <0.001      | 0.9871  |                     |         |
| Kidney disease         | 0                             | 1 (0.5)                   | <0.001      | 0.9871  |                     |         |
| Mental health problem  | 17 (17)                       | 19 (11)                   | 1.8 (0.9–3.6) | 0.1139  |                     |         |
| Neurologic problem     | 4 (4)                         | 8 (4)                     | 0.9 (0.3–3.1) | 0.8809  |                     |         |
| Immunosupression       | 1 (1)                         | 2 (1)                     | 0.9 (0.1–10.2) | 0.942   |                     |         |
| Obstructive sleep apnea| 10 (10)                       | 4 (2)                     | 5.0 (1.5–16.3) | 0.0003  |                     |         |
| Lung disease           | 10 (10)                       | 4 (2)                     | 5.0 (1.5–16.3) | 0.0003  |                     |         |
| Diabetes               | 14 (14)                       | 2 (1)                     | 14.7 (3.3–66.3) | 0.0005  | 20 (4.0–103.0)      | 0.0003  |
| Metabolic disorder     | 1 (1)                         | 2 (1)                     | 0.9 (0.1–10.2) | 0.942   |                     |         |
| Liver disease          | 5 (5)                         | 0                         | >999.9      | 0.9798  |                     |         |
| Blood disorder         | 4 (4)                         | 8 (4)                     | 0.9 (0.3–3.1) | 0.8809  |                     |         |
| Pregnancy              | 40 (40)                       | 7 (4)                     | 16.9 (7.2–39.6) | <0.001  | 28 (11.0–70.0)      | <0.0001 |
| **Smoking status**     |                               |                           |             |         |                     |         |
| Nonsmoker              | 53 (54)                       | 130 (72)                  | Referent    | 0.0057  |                     |         |
| Current smoker         | 24 (24)                       | 32 (18)                   | 1.8 (1.0–3.4) | 0.0057  |                     |         |
| Former smoker          | 22 (22)                       | 19 (11)                   | 2.8 (1.4–5.7) | 0.0003  |                     |         |
| **Influenza vaccine in 2009¶** | 20 (20) | 30 (17) | 1.3 (0.7–2.4) | 0.4262  |                     |         |

*OR, odds ratio; CI, confidence interval.
†8 controls and 6 case-patients missing data.
§1 control and 3 case-patients missing data.
¶1 case-patient missing data.
Table 3. Risk factors for mechanical ventilation because of pandemic (H1N1) 2009 infection, Sydney, Australia, 2009*

| Patient characteristic | No. (%) case-patients, n = 37 | No. (%) controls, n = 603 | OR (95% CI) | p value | Adjusted OR (95% CI) | p value |
|------------------------|--------------------------------|---------------------------|-------------|---------|---------------------|---------|
| **Sex**                |                                |                           |             |         |                     |         |
| M                      | 11 (30)                        | 207 (34)                  | 1.2 (0.6–2.6) | 0.5674  |                     |         |
| F                      | 26 (70)                        | 396 (66)                  |             |         |                     |         |
| **Age, y**             |                                |                           |             |         |                     |         |
| 16–25                  | 3 (8)                          | 61 (10)                   | 3.7 (0.7–19) | 5.5 (0.7–42.0) | 1.2 (0.6–2.6) | 0.5674 |
| 26–35                  | 11 (30)                        | 92 (15)                   | 9.1 (2.5–33.3) | 12.2 (2.5–58.2) |             |         |
| 36–45                  | 12 (32)                        | 111 (18)                  | 8.2 (2.3–29.7) | 10.4 (2.3–48.3) |             |         |
| 46–55                  | 8 (22)                         | 111 (18)                  | 5.5 (1.4–21.0) | 10.2 (2.3–45.9) |             |         |
| >55                    | 3 (8)                          | 228 (38)                  |             |         | 0.0114              | 0.0176  |
| **Aboriginal status**  |                                |                           |             |         |                     |         |
| Nonindigenous          | 36 (97)                        | 596 (99)                  |             |         |                     |         |
| Indigenous             | 1 (3)                          | 7 (1)                     | 2.4 (0.3–19.7) | 0.426  |                     |         |
| **Body mass index†**   |                                |                           |             |         |                     |         |
| Underweight (<18.5)    | 3 (9)                          | 15 (3)                    | 8.6 (2.0–37.9) | 10.6 (1.9–58.9) | 0.0004   | 0.0022  |
| Normal (18.5–24.9)     | 6 (17)                         | 259 (45)                  |             |         |                     |         |
| Overweight (25.0–29.9) | 10 (29)                        | 175 (30)                  | 2.5 (0.9–6.9) | 3.2 (1.0–10.3) |             |         |
| Obese 1 (30.0–34.9)    | 5 (14)                         | 79 (14)                   | 2.7 (0.8–9.2) | 1.8 (0.5–7.4)  |             |         |
| Obese 2 (35.0–39.9)    | 5 (14)                         | 29 (5)                    | 7.4 (2.1–25.9) | 9.8 (2.4–40.1) |             |         |
| Obese 3 (>40)          | 6 (17)                         | 21 (4)                    | 12.3 (3.7–41.6) | 11.6 (2.7–49.3) |             |         |
| **Health condition‡**  |                                |                           |             |         |                     |         |
| Asthma                 | 13 (65)                        | 93 (15)                   |             |         |                     |         |
| No regular medication  | 5 (14)                         | 48 (8)                    | 2.2 (0.8–6.1) | 0.0061  |                     |         |
| Regular medication     | 8 (22)                         | 45 (7)                    | 3.8 (1.6–8.9) |             |                     |         |
| Heart disease§         | 3 (9)                          | 41 (7)                    | 1.3 (0.4–4.3) | 0.7136  |                     |         |
| Kidney disease¶        | 1 (3)                          | 8 (1)                     | 2.1 (0.3–16.9) | 0.5013  |                     |         |
| Mental health problem  | 6 (16)                         | 49 (8)                    | 2.2 (0.9–5.5) | 0.0958  |                     |         |
| Neurologic problem     | 3 (8)                          | 42 (7)                    | 1.2 (0.3–4.0) | 0.792   |                     |         |
| Immunosuppression      | 1 (3)                          | 22 (4)                    | 0.7 (0.1–5.6) | 0.7655  |                     |         |
| Obstructive sleep apnea| 2 (5)                          | 23 (4)                    | 1.4 (0.3–6.4) | 0.6296  |                     |         |
| Lung disease           | 6 (16)                         | 31 (5)                    | 3.6 (1.4–9.2) | 0.0084  | 8.6 (2.6–28.5)      | 0.0005  |
| Diabetes               | 5 (14)                         | 38 (6)                    | 2.3 (0.9–6.3) | 0.0977  | 4.4 (1.2–15.6)      | 0.0383  |
| Liver disease          | 2 (5)                          | 20 (3)                    | 1.7 (0.4–7.4) | 0.503   |                     |         |
| Pregnancy              | 8 (22)                         | 7 (1)                     | 23.4 (8.0–69.2) <0.001 | 40.5 (9.7–168.1) | <0.0001 |
| **Smoking status**     |                                |                           |             |         |                     |         |
| Nonsmoker              | 17 (46)                        | 372 (62)                  | 2.4 (1.0–5.5) | 0.0325  |                     |         |
| Current or former smoker| 20 (54)                        | 231 (38)                  | 1.9 (1.0–3.7) | 0.0605  |                     |         |
| **Influenza vaccine in 2009** | 20 (54) | 202 (34) | 0.3 (0.1–0.8) | 0.0163  |                     |         |

*OR, odds ratio; CI, confidence interval.
†Data missing for 2 case-patients and 25 controls.
‡Groups are not mutually exclusive.
§Date missing for 2 case-patients and 12 controls.
¶Data missing for 3 controls.

Discussion

We found that pregnancy, lung disease, immune suppression, asthma, diabetes, heart disease, and a history of smoking were associated with hospitalization from pandemic (H1N1) 2009 infection. Among women of childbearing age, pregnancy was the single greatest risk factor for hospitalization, followed by diabetes, history of asthma requiring regular medication, and lung disease. Obesity was not an independent risk factor for hospitalization although it was a risk factor for mechanical ventilation. The majority of case-patients sought medical attention within 48 hours of symptoms. This study did not identify any particular risk groups that were less likely to seek early medical attention.

Our study was designed to identify risk factors for moderate to severe illness resulting from influenza (as measured by requirement for hospital admission), not risk factors for acquiring influenza. Controls for the study were therefore selected from the community rather than nonhospitalized case-patients. When controls who reported

both those with reported risk factors and those with no risk factors (80% and 79%, respectively). There was no significant difference in individual underlying risk factors between case-patients who sought medical attention within 48 hours of symptoms and those who did not (Table 4).
influenza-like-illness were compared with controls without these symptoms, there was no significant difference in risk factors other than age. This finding suggests that apart from age (which is likely to reflect past infection with influenza strains that protected against pandemic [H1N1] 2009) (25), other participant characteristics were not important for determining susceptibility for infection.

Our data are subject to several limitations. First, compared with the adult population in Sydney, controls were older and a higher proportion were women, introducing the possibility of bias if the groups were not otherwise similar. However, our analysis adjusted for age and sex, and the findings were consistent with those of similar studies examining risk factors for seasonal influenza (3–5,6). When the model was restricted to gender, the results were similar to the final model. These findings suggest that the potential bias from control selection on the final model was minimal. Second, risk factor status was determined by self-report for case-patients and controls. However, public messaging during the pandemic relied on

Table 4. Comparison of characteristics of patients with cases of pandemic (H1N1) 2009 influenza by time from symptom onset to medical attention, Sydney, Australia, 2009*

| Patient characteristic | Medical attention within 48 h | OR (95% CI) | p value |
|------------------------|-----------------------------|-------------|---------|
|                        | Yes, no. (%) patients, n = 235 | No, no. (%) patients, n = 60 |              |         |
| Sex                    |                             |             |         |
| M                      | 97 (41)                     | 24 (40)     | 1.1 (0.6–1.9) | 0.8576  |
| F                      | 138 (59)                    | 36 (60)     |         |         |
| Age, y                 |                             |             |         |
| 16–25                  | 33 (14)                     | 5 (8)       | 1.1 (0.3–4.3) |         |
| 26–35                  | 44 (19)                     | 9 (15)      | 0.8 (0.3–2.8) |         |
| 36–45                  | 47 (20)                     | 11 (18)     | 0.7 (0.2–2.3) |         |
| 46–65                  | 50 (21)                     | 20 (33)     | 0.4 (0.1–1.3) |         |
| 56–65                  | 32 (14)                     | 10 (17)     | 0.6 (0.2–1.8) |         |
| >65                    | 29 (12)                     | 5 (8)       |         |         |
| Aboriginal status      |                             |             |         |
| Nonindigenous          | 229 (97)                    | 58 (97)     | 0.8 (0.1–3.9) | 0.7409  |
| Indigenous             | 6 (3)                       | 2 (3)       |         |         |
| Body mass index†       |                             |             |         |
| Underweight (<18.5)    | 13 (6)                      | 2 (3)       | 1.6 (0.3–7.8) |         |
| Normal (18.5–24.9)     | 65 (28)                     | 16 (27)     |         | 0.4457  |
| Overweight (25.0–29.9) | 67 (29)                     | 10 (17)     | 1.6 (0.7–3.9) |         |
| Obese 1 (30–34.9)      | 38 (16)                     | 12 (20)     | 0.8 (0.3–1.8) |         |
| Obese 2 (35–39.9)      | 23 (10)                     | 6 (10)      | 0.9 (0.3–2.7) |         |
| Obese 3 (>40)          | 19 (8)                      | 8 (13)      | 0.6 (0.2–1.6) |         |
| Health condition‡      |                             |             |         |
| Asthma                 | 89 (38)                     | 24 (40)     | 1.4 (0.7–2.6) |         |
| No regular medication  | 16 (7)                      | 9 (15)      | 1.2 (0.5–2.8) | 0.703   |
| Regular medication     | 73 (31)                     | 15 (25)     | 1.0 (0.2–4.9) | 0.9785  |
| Heart disease§         | 31 (13)                     | 7 (12)      | 0.4 (0.2–0.8) | 0.0129  |
| Kidney disease         | 8 (3)                       | 2 (3)       | 0.4 (0.2–1.0) | 0.0586  |
| Mental health problem  | 34 (14)                     | 17 (28)     | 1.0 (0.4–2.4) | 0.8803  |
| Neurologic problem     | 14 (6)                      | 8 (13)      | 1.1 (0.5–2.2) | 0.828   |
| Immunosuppression      | 22 (9)                      | 6 (10)      | 1.3 (0.3–2.7) | 0.5141  |
| Obstructive sleep apnea| 26 (11)                     | 10 (17)     | 0.8 (0.3–2.3) | 0.6823  |
| Lung disease           | 46 (20)                     | 11 (18)     | 1.3 (0.5–3.2) | 0.6008  |
| Diabetes               | 48 (20)                     | 10 (17)     | 1.3 (0.6–2.7) |         |
| Liver disease          | 16 (7)                      | 5 (8)       | 0.8 (0.3–2.3) |         |
| Pregnancy              | 33 (14)                     | 7 (12)      | 1.3 (0.5–3.2) |         |
| Smoking status¶        |                             |             |         |
| Nonsmoker              | 113 (48)                    | 26 (43)     |         |         |
| Current or former smoker| 121 (51)                  | 34 (57)     | 0.8 (0.5–1.5) | 0.493   |
| Influenza vaccine in 2009# | 86 (37)                  | 19 (32)     | 1.3 (0.7–2.3) | 0.4507  |

*OR, odds ratio; CI, confidence interval.
†Data missing for 10 case-patients who received medical attention within 48 h and 6 who did not.
‡Groups are not mutually exclusive.
§Data were missing for 6 case-patients who received medical attention within 48 h.
¶Data were missing for 1 case-patient who received medical attention within 48 h.
#Vaccination information was missing for 2 case-patients and 1 control.
the persons recognizing that they were in a high-risk group. For this reason, self-reported risk factors were thought to be a good indication of identified risk. However, undiagnosed or unacknowledged medical conditions would not have been captured in our study and could underestimate the effect of some risk factors. Third, the underlying reason for admission to hospital for patients (whether specifically caused by the infection or because of preexisting illness or both) was not determined in this study. Case-patients were selected for inclusion in the study if they met the pandemic (H1N1) 2009 case definition, were hospitalized, and had onset of symptoms >2 days before admission. Fourth, although pregnancy was identified as an independent risk factor for hospitalization, the magnitude of this risk may be biased upward if clinicians had a lower threshold for admitting pregnant women as a precaution, particularly in later stages of pregnancy. Fifth, patients who died following pandemic (H1N1) 2009 infection were excluded from the study, thereby excluding those with the most severe disease. Although patients who died were obviously unable to be interviewed, information regarding the presence of underlying medical conditions was collected from the treating clinicians. During the study period, there were 23 deaths that met the study’s case definition. Similar to interviewed case-patients, 20 (87%) of the patients who died were reported to have ≥1 significant risk factor. However, a higher proportion of patients who died were reported as having lung disease (60% vs. 19%), being a current smoker (35% vs. 22%), and having immune suppression (25% vs. 10%) when compared with study participants. Deceased patients were significantly older (median 59 years, range 23–85 years) compared with surviving patients (median 45 years, range 16–88 years) included in the study (p<0.001).

Descriptive studies of pandemic (H1N1) 2009 infection have reported obesity, heart disease, diabetes, pregnancy (26–28), kidney disease, neurologic disease, immune suppression, lung disease, asthma, smoking, and relatively young age (29,30) as the most common concurrent conditions for hospitalized patients (11–20). Given that many of these underlying medical conditions do not occur in isolation, our analytical study was able to ascertain which of these were independently associated with hospitalization from pandemic (H1N1) 2009.

Although high rates of pandemic (H1N1) 2009 infection have been reported from indigenous people in other reports (31), our study lacked sufficient power to explore the independent impact of being Aboriginal on the risk factor of moderate to severe disease. However, among those Aboriginal case-patients included, all reported a history of other independent risk factors. These data may suggest that it is the high prevalence of risk factors for severe disease that place Aboriginal people at an increased risk rather than genetic susceptibility.

BMI was not independently associated with increased risk for hospitalization with pandemic (H1N1) 2009. Obesity appears to be a confounder of other risk factors for overweight patients. Of the 58 case-patients with BMI >35 (very obese), 55 (95%) reported ≥1 significant risk factor, including smoking (35/55, 64%), asthma (32/55, 58%), and diabetes (18/55, 33%). Further analysis suggested that obesity was independently associated with increased risk of ventilation in our study. Of the 35 ventilated case-patients, 11 reported a BMI >35, and all but 2 patients reported other significant risk factors.

Our study highlights the increased risk of moderate to severe illness from pandemic (H1N1) 2009 for pregnant women and introduces smoking as an independent risk factor for hospitalization from pandemic (H1N1) 2009. In addition, our study provides evidence to support the continuation of influenza prevention efforts (including vaccination) targeted to persons with lung disease, immune suppression, asthma, diabetes, and heart disease. Although Aboriginal status and obesity may not be independent risk factors for severe disease, they indicate the likely presence of other risk factors, and so prevention messages should continue to be directed to these groups.

Acknowledgments

We thank Kerry Chant, Judy Simpson, and the New South Wales public health network, including laboratory staff.

Ms Ward is an epidemiologist and manager of surveillance in the Communicable Diseases Branch at New South Wales Health. Her research interests include infectious disease outbreak management and response.

References

1. Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children—southern California, March–April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:400–2.
2. Centers for Disease Control and Prevention. Outbreak of swine-origin influenza A (H1N1) virus infection—Mexico, March–April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:467–70.
3. Fielding J, Higgins N, Gregory J, Grant K, Catton M, Bergeri I, et al. Pandemic H1N1 influenza surveillance in Victoria, Australia, April–September, 2009. Euro Surveill. 2009;14 pii:193568.
4. Libster R, Bugna J, Coviello S, Hijano DR, Dunaeiwsky M, Reynolds N, et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med. 2010;362:45–55. doi:10.1056/NEJMoa0907673
5. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009;361:1935–44. doi:10.1056/NEJMoa0906695
6. Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007;25:846–55. doi:10.1016/j.vaccine.2006.09.041
7. Thompson WW, Shay DK, Weintrab E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–86. doi:10.1001/jama.289.2.179

8. Thompson WW, Shay DK, Weintrab E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333–40. doi:10.1001/jama.292.11.1333

9. Babcock HM, Merz LR, Dubberke ER, Fraser VJ. Case–control study of clinical features of influenza in hospitalized patients. Infect Control Hosp Epidemiol. 2008;29:921–6. doi:10.1086/590663

10. Bridges CB, Winquist AG, Fukuda K, Cox NJ, Singleton JA, Strikas RA, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–38.

11. Cullen G, Martin J, O’Donnell J, Boland M, Canny M, Keane E, et al. Surveillance of the first 205 confirmed hospitalised cases of pandemic H1N1 influenza in Ireland, 28 April–3 October 2009. Euro Surveill. 2009;14 pii:19389.

12. Ugarte S, Arancibia F, Soto R. Influenza A pandemics: clinical and organizational aspects: the experience in Chile. Crit Care Med. 2010;38(Suppl):e133–7. doi:10.1097/CCM.0b013e3181c87716

13. Strategic Advisory Group of Experts on Immunization—report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009. Wkly Epidemiol Rec. 2009;84:301–4.

14. Castro-Jiménez MÁ, Castillo-Pabón JO, Rey-Benito GJ, Pulido-Domínguez PA, Barbosa-Ramírez J, Velandia-Rodríguez DA, et al. Epidemiologic analysis of the laboratory-confirmed cases of influenza A(H1N1)v in Colombia. Euro Surveill. 2009;14:19284.

15. Novel influenza A(H1N1) Investigation Team. Description of the early stage of pandemic (H1N1) 2009 in Germany, 27 April–16 June 2009. Euro Surveill. 2009;14 pii:19295.

16. Kumar A, Zarichanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302:1872–9. doi:10.1001/jama.2009.1496

17. Domínguez-Cherit G, Lapinsky SE, Macias AR, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically ill patients with 2009 influenza A (H1N1) in Mexico. JAMA. 2009;302:1880–7. doi:10.1001/ jama.2009.1536

18. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Scheckter R, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302:1896–902. doi:10.1001/jama.2009.1583

19. ANZIC Influenza Investigators; Webb SA, Pettiti V, Seppelt I, Bellomo R, Bailey M, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009;361:1925–34. doi:10.1056/NEJMoa0908481

20. Centers for Disease Control and Prevention. Patients hospitalized with 2009 pandemic influenza A (H1N1)—New York City, May 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1436–40.

21. Government of New South Wales. Public Health Act 1991 [cited 2009 Dec 15]. http://www.health.nsw.gov.au/factsheets/guideline/swine_flu.html

22. New South Wales public health response guidelines: H1N1 influenza 09 Infection Protect Phase [cited 2009 Dec 15]. http://www. health.nsw.gov.au/act+10+1991+FIRST+0+N

23. Australian Department of Health and Ageing. Protect Phase—Annex to the Australian Health Management Plan for Pandemic Influenza, version 3.0, 21 September 2009 [cited 2009 Dec 15]. http://www. healthemergency.gov.au/internet/healthemergency/publishing. nsf/Content/protect-annex

24. Barr M, Baker D, Gorringe M, Fritsche L. NSW Population Health Survey: description of methods. Sydney: Centre for Epidemiology and Research, NSW Department of Health, 2008 [cited 2010 Feb 18]. http://www.health.nsw.gov.au/resources/publichealth/surveys/ health_survey_method.asp

25. Rizzo C, Rota MC, Bella A, Alfonsi V, Decli S, Caporali MG, et al. Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. Vaccine. 2010;28:3558–62. doi:10.1016/j.vaccine.2010.03.006

26. Hewagama S, Walker SP, Stuart RL, Gordon C, Johnson PD, Friedman ND, et al. 2009 H1N1 influenza A and pregnancy outcomes in Victoria, Australia. Clin Infect Dis. 2010;50:686–90. doi:10.1086/650460

27. Rasmussen SA, Jamieson DJ, Bresse JS. Pandemic influenza and pregnant women. Emerg Infect Dis. 2008;14:95–100. doi:10.3201/ eid1041.070667

28. Jamieson DJ, Honein M, Rasmussen SA, Williams JL, Swerdlov DL, Biggerstaff MS, et al. 2009 H1N1 influenza virus infection during pregnancy in the USA. Lancet. 2009;374:451–8. doi:10.1016/ S0140-6736(09)61304-0

29. Creanga AA, Johnson TF, Graizter SB, Harman LK, Al-Samarrai T, Schwarz AG, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol. 2010;115:717–26. doi:10.1097/AOG.0b013e3181d579c7

30. Simonson L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis. 1998;178:53–60.

31. La Ruche G, Tarantola A, Barboza P, Vaillant L, Gueguen J, Gastel-Velut-de-Cissey M, et al. The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. Euro Surveill. 2009;14 pii:19366.

Address for correspondence: Paula J. Spokes, New South Wales Department of Health, 73 Miller St, Sydney, NSW 2060, Australia; email: ps spoke@doh.health.nsw.gov.au